|
Session 125
Poster Abstracts
Clinical Pharmacology of Reverse Transcriptase Inhibitors
Tuesday, 1-4 pm
Room: Hall A |
| 754 |
Compartmental Kinetics of Intracellular Tenofovir
Courtney Fletcher*1, T King1, L Bushman1, J Kiser1, P Anderson1, J Brenchley2, D Douek2, and T Schacker3
1Univ of Colorado Hlth Sci Ctr, Denver, US; 2NIAID, NIH, Bethesda, MD, US; and 3Univ of Minnesota, Minneapolis, US |
| 755 |
Intracellular Accumulation of Tenofovir and Emtricitabine in vitro Highlight the Inhibitor Role of Efavirenz for Multridrug Resistance-Associated Protein 1, MRP1
Laurence Bousquet*1, A Pruvost1, N Didier1, R Farinotti2, and A Mabondzo1
1CEA, iBiTecS, Gif sur Yvette, France and 2Univ Paris Sud XI, Chatenay-Malabry, France |
756
 |
Positron Emission Tomography Agent for Non-invasive Imaging of Antiretroviral Drug Penetration and Kinetics in vivo
Michele Di Mascio*1, S Srinivasula2, M Collins3, E Lim4, L Cheng1, and D Kiesewetter5
1NIAID, NIH, Bethesda, MD, US; 2SAIC-Frederick, MD, US; 3Bioqual Inc, Rockville, MD, US; 4Univ of Pennsylvania, Philadelphia, US; and 5Natl Inst of Biomed Imaging and BioEngineering, NIH, Bethesda, MD,US |
757
|
Comparison of Package-insert Recommendations for Renal Dosing and Prescribed Dosing of Products Containing Tenofovir: The VA Experience
Barbara Phillips*, P Belperio, L Mole, and V Katseva
Ctr for Quality Mgmt in Publ Hlth, Veterans Hlth Admin, Palo Alto, CA, US |
758
|
Pharmacological Mechanisms Leading to Early Virologic Failure of 2 Antiretroviral Regimens: Didanosine, Lamivudine, and Tenofovir, and Abacavir, Lamivudine, and Tenofovir
Lucun Bi*1, J Russell1, N Mordwinkin1, J Lam2, and S Louie1
1Univ of Southern California Sch of Pharmacy, Los Angeles, US and 2Loma Linda Univ Sch of Pharmacy, CA, US |
759
|
Pharmacogenetics of Plasma Drug Exposure and Treatment Outcomes with Efavirenz-containing Regimens: An ACTG Study
David Haas*1, H Ribaudo2, A Motsinger3, B Schackman4, R Gulick4, E Acosta5, M Schwab6, E Schaeffeler6, G Morse7, G Robbins8, and The AIDS Clinical Trials Group
1Vanderbilt Univ, Nashville, TN, US; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3North Carolina State Univ, Raleigh, US; 4Weill Med Coll of Cornell Univ, New York, NY, US; 5Univ of Alabama at Birmingham, US; 6Margarete Fischer-Bosch Inst for Clinical Pharma, Stuttgart, Germany; 7State Univ of New York at Buffalo, US; and 8Harvard Univ, Boston, MA, US |
760
|
Pharmacokinetics of Nevirapine and Rifampicin in TB/HIV Co-infected Patients in Burkina Faso
Alberto Matteelli*1, N Saleri1,3, M Regazzi2, P Villani2, V Bonkoungou3, J Simpore3, A Carvalho1, M Cusato2, G Carosi1, and M Dembele3
1Inst of Infectious and Tropical Diseases, Univ of Brescia, Italy; 2Inst of Pharmacology, IRCCS, San Matteo, Pavia, Italy; and 3Natl TB Prgm, Ministry of Hlth, Burkina Faso |
761
|
Efavirenz Induces CYP450 2B6 Activity as Measured by Bupropion Hydroxylation in Healthy Subjects
Sarah Robertson*1, F Maldarelli2, V Natarajan3, E Formentini4, R Alfaro5, and S Penzak5
1US Food and Drug Admin, Silver Spring, MD, US; 2NCI, Bethesda, MD, US; 3SAIC-Frederick, MD, US; 4NIH, Bethesda, MD, US; and 5Clinical Res Ctr, NIH, Bethesda, MD, US |
762
|
Pharmacokinetics and Pharmacodynamics of the NNRTI TMC125 in Treatment-experienced HIV-1-infected Patients: Pooled 24-week Results of DUET-1 and DUET-2
Thomas Kakuda*1, J Wade2, E Snoeck2, M Peeters3, C Corbett3, G De Smedt3, L Leopold1, J Vingerhoets3, B Woodfall3, and R Hoetelmans3
1Tibotec, Inc, Yardley, PA, US; 2Exprimo NV, Mechelen, Belgium; and 3Tibotec BVBA, Mechelen, Belgium |
763
|
Pharmacokinetic Interaction of the Next Generation NNRTI UK-453,061 with Other Antiretrovirals and Assessment of Safety and Tolerability in Healthy Male Subjects
G Langdon1, J Davis1, G Layton1, H Choo2, M N Ndongo3, A Milton4, and Manoli Vourvahis*4
1Pfizer Global R&D, Sandwich, UK; 2Pfizer Res Clin, Singapore Gen Hosp; 3Pfizer Res Clin, Erasme, Brussels, Belgium; and 4Pfizer Global R&D, New London, CT, US |
764
|
Dose-escalation Safety, Tolerability, and Pharmacokinetics of a Novel HIV-1 NNRTI [IDX899] in Healthy Subjects
Douglas Mayers*, M Hard, D Damphousse, B Fielman, J Sullivan-Bolyai, B Belanger, and X J Zhou
Idenix Pharma, Inc, Cambridge, MA, US |
|
